Trial Profile
A Phase III Investigation of Topical Application of Cocaine HCl 4% and 10% on Safety and Efficacy in Local (Topical) Anesthesia for Diagnostic Procedures and Surgeries on or Through Accessible Mucous Membranes of the Nasal Cavities.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 15 Jan 2020
Price :
$35
*
At a glance
- Drugs Cocaine (Primary)
- Indications Procedural pain
- Focus Registrational; Therapeutic Use
- Sponsors Lannett
- 13 Jan 2020 According to a Lannett media release, U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA), submitted under the 505(b)(2) regulatory pathway, for Cocaine Hydrochloride (HCl) Nasal Solution 4% (40 mg/mL), the company's branded local anesthetic product.The submission was supported by two Phase III s well as a Phase I pharmacokinetic study
- 01 Dec 2017 According to a Lannett media release, this FDA acceptance is based, on the data of this trial and other phase III trial (211802) along with the data of a pharmacokinetic phase 1 trial.
- 01 Dec 2017 According to a Lannett media release, the U.S. Food and Drug Administration (FDA) has accepted a 505(b)(2) New Drug Application (NDA) filing for Cocaine Hydrochloride (HCl) Topical Solution, 4% and 10%, with a proposed trade name of Numbrino™, for the introduction of local (topical) anesthesia for diagnostic procedures and surgeries on or through the accessible mucous membranes of the nasal cavities. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of July 21, 2018.